1. Home
  2. CLAR vs ENGN Comparison

CLAR vs ENGN Comparison

Compare CLAR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clarus Corporation

CLAR

Clarus Corporation

HOLD

Current Price

$3.66

Market Cap

104.9M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.85

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLAR
ENGN
Founded
1957
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
104.9M
117.2M
IPO Year
1998
2023

Fundamental Metrics

Financial Performance
Metric
CLAR
ENGN
Price
$3.66
$1.85
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$4.08
$21.08
AVG Volume (30 Days)
134.6K
681.5K
Earning Date
05-07-2026
06-11-2026
Dividend Yield
3.80%
N/A
EPS Growth
11.68
56.85
EPS
0.04
N/A
Revenue
$228,000.00
N/A
Revenue This Year
$5.27
N/A
Revenue Next Year
$3.99
N/A
P/E Ratio
$93.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.53
$1.40
52 Week High
$4.03
$12.25

Technical Indicators

Market Signals
Indicator
CLAR
ENGN
Relative Strength Index (RSI) 53.15 51.67
Support Level $3.52 $1.67
Resistance Level $3.71 $1.96
Average True Range (ATR) 0.11 0.07
MACD -0.02 0.02
Stochastic Oscillator 33.33 63.79

Price Performance

Historical Comparison
CLAR
ENGN

About CLAR Clarus Corporation

Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: